Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.

Kirkwood JM, Farkas DL, Chakraborty A, Dyer KF, Tweardy DJ, Abernethy JL, Edington HD, Donnelly SS, Becker D.

Mol Med. 1999 Jan;5(1):11-20.

3.

STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.

Wang W, Edington HD, Rao UN, Jukic DM, Wang H, Shipe-Spotloe JM, Kirkwood JM.

J Invest Dermatol. 2008 Aug;128(8):1997-2002. doi: 10.1038/jid.2008.26. Epub 2008 Feb 28.

4.

Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.

Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, Walker MJ, Carson WE 3rd.

Cancer Immunol Immunother. 2005 Sep;54(9):815-25. Epub 2005 Jan 25.

PMID:
15668815
5.

Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.

Humpoliková-Adámková L, Kovarík J, Dusek L, Lauerová L, Boudný V, Fait V, Fojtová M, Krejcí E, Kovarík A.

Eur J Cancer. 2009 May;45(7):1315-23. doi: 10.1016/j.ejca.2009.01.009. Epub 2009 Feb 14.

PMID:
19232485
6.

Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.

Lesinski GB, Kondadasula SV, Crespin T, Shen L, Kendra K, Walker M, Carson WE 3rd.

J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42.

PMID:
15339971
7.

Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma.

Yang P, Farkas DL, Kirkwood JM, Abernethy JL, Edington HD, Becker D.

Mol Med. 1999 Dec;5(12):785-94.

9.

The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.

Badgwell B, Lesinski GB, Magro C, Abood G, Skaf A, Carson W 3rd.

J Surg Res. 2004 Jan;116(1):129-36.

PMID:
14732359
10.

Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).

Chawla-Sarkar M, Leaman DW, Jacobs BS, Tuthill RJ, Chatterjee-Kishore M, Stark GR, Borden EC.

J Interferon Cytokine Res. 2002 May;22(5):603-13.

PMID:
12060499
11.

Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.

Lesinski GB, Trefry J, Brasdovich M, Kondadasula SV, Sackey K, Zimmerer JM, Chaudhury AR, Yu L, Zhang X, Crespin TR, Walker MJ, Carson WE 3rd.

Clin Cancer Res. 2007 Sep 1;13(17):5010-9.

13.
15.

IFN-alpha induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3.

Ziegler-Heitbrock L, Lötzerich M, Schaefer A, Werner T, Frankenberger M, Benkhart E.

J Immunol. 2003 Jul 1;171(1):285-90.

16.

Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ.

J Biol Chem. 1997 Nov 7;272(45):28779-85.

17.

Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes.

Radaeva S, Jaruga B, Hong F, Kim WH, Fan S, Cai H, Strom S, Liu Y, El-Assal O, Gao B.

Gastroenterology. 2002 Apr;122(4):1020-34.

PMID:
11910354
18.

Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

von Felbert V, Córdoba F, Weissenberger J, Vallan C, Kato M, Nakashima I, Braathen LR, Weis J.

Am J Pathol. 2005 Mar;166(3):831-41.

19.

Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell.

Ho LJ, Hung LF, Weng CY, Wu WL, Chou P, Lin YL, Chang DM, Tai TY, Lai JH.

J Immunol. 2005 Jun 15;174(12):8163-72.

Supplemental Content

Support Center